Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
DNA vaccines have come a long way since the 1990s, and a new review in Genes & Diseases says they're poised to transform medicine. From cancer immunotherapy to pandemic preparedness, these genetic instruction-based vaccines can be rapidly designed, scaled, and adapted. But hurdles like low immunogenicity and limited regulatory approvals still stand in the way of widespread use.
DNA vaccines work differently from traditional shots — instead of delivering a weakened pathogen or protein, they hand your cells a genetic blueprint to produce an antigen, triggering both antibody and cellular immune responses. A sweeping new review in Genes & Diseases traces the evolution of this platform from early 1990s concepts to today's sophisticated tools, including plasmid-based vaccines and viral vector systems.
The COVID-19 pandemic gave DNA vaccine research a serious boost, spotlighting the value of platforms that can be quickly redesigned as threats emerge. The authorization of ZyCoV-D — the first plasmid DNA vaccine approved for human use — marked a key milestone. Beyond infectious diseases, therapeutic DNA vaccines are now being explored for cancers like melanoma, prostate, cervical, and glioblastoma, as well as chronic infections like HIV and hepatitis B.
Key Takeaways:
Why it matters: DNA vaccines offer thermal stability, low production costs, and rapid scalability — qualities that could be game-changing for global vaccination programs and future pandemic response. Solving the remaining technical hurdles could unlock a truly versatile medical platform.
